A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Phase of Trial: Phase II/III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- 03 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2016 to 1 Jun 2019.
- 03 Feb 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Oct 2016 to 1 Jun 2018.
- 21 Jan 2015 New trial record